Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT ID: NCT04423718

Last Updated: 2025-08-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1011 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-11

Study Completion Date

2024-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid or blood into the light sensitive lining inside the eye (retina). The fluid buildup causes the central part of the retina (macula) responsible for sharp, straight-ahead vision to swell and thicken (edema), which distorts vision.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Up to Week 108: Participant and Investigator masked. Week 108 to Week 156: Participant and Investigator unmasked to treatment intervals.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aflibercept 2q8

In the double-masked study part (Years 1 and 2), Aflibercept 2 mg administered every 8 weeks after a loading phase. (Active Comparator) In Year 3, high dose aflibercept administered according to individual patient response. (Experimental)

Group Type ACTIVE_COMPARATOR

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Intervention Type DRUG

Solution in Vial, intravitreal (IVT) injection

Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

Intervention Type DRUG

Solution in Vial, 2 mg, intravitreal (IVT) injection

Aflibercept HDq12

Aflibercept high dose (HD) administered every 12 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.

Group Type EXPERIMENTAL

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Intervention Type DRUG

Solution in Vial, intravitreal (IVT) injection

Aflibercept HDq16

Aflibercept high dose administered every 16 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.

Group Type EXPERIMENTAL

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Intervention Type DRUG

Solution in Vial, intravitreal (IVT) injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Solution in Vial, intravitreal (IVT) injection

Intervention Type DRUG

Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

Solution in Vial, 2 mg, intravitreal (IVT) injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.
* Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.
* BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
* Decrease in BCVA determined to be primarily the result of nAMD in the study eye.
* Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical studies.


* At least one BCVA value and one central subfield retinal thickness (CST) value from measurements at one of the following visits: Visit 24 (Week 84), Visit 25 (Week 88) or Visit 26 (Week 92).
* Participant is enrolled at a site that participates in the extension period.

Exclusion Criteria

* Causes of CNV other than nAMD in the study eye.
* Scar, fibrosis, or atrophy involving the central subfield in the study eye.
* Presence of retinal pigment epithelial tears or rips involving the central subfield in the study eye.
* Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with anti-glaucoma medication) in the study eye.
* History of idiopathic or autoimmune uveitis in the study eye.
* Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
* History or clinical evidence of diabetic retinopathy, diabetic macular edema, or any retinal vascular disease other than nAMD in either eye.
* Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
* Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg).
* Any prior or concomitant ocular (in the study eye) or systemic treatment (with an investigational or approved, anti-VEGF or other agent) or surgery for nAMD, except dietary supplements or vitamins.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role collaborator

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Retina & Vitreous Consultants - Central Phoenix Phoenix

Phoenix, Arizona, United States

Site Status

Retina Consultants of Orange County - Fullerton

Fullerton, California, United States

Site Status

Northern California Retina Vitreous Associates - Mountain View Office

Mountain View, California, United States

Site Status

Azul Vision Pasadena

Pasadena, California, United States

Site Status

Retina Consultants San Diego - Poway

Poway, California, United States

Site Status

Retina Consultants of Southern California

Redlands, California, United States

Site Status

Kaiser Permanente Riverside Medical Center - Cardiology

Riverside, California, United States

Site Status

Perlman Medical Offices at UC San Diego Health - Endocrinology

San Diego, California, United States

Site Status

Retina Consultants of Southern Colorado, PC

Colorado Springs, Colorado, United States

Site Status

New England Retina Associates

New London, Connecticut, United States

Site Status

Rand Eye Institute

Deerfield Beach, Florida, United States

Site Status

Retina Group of Florida - Fort Lauderdale

Fort Lauderdale, Florida, United States

Site Status

Vitreo Retinal Associates PA - The Millennium Center Location

Gainesville, Florida, United States

Site Status

Florida Retina Institute- Jacksonville Oak

Jacksonville, Florida, United States

Site Status

Florida Eye Associates - Melbourne Main Office

Melbourne, Florida, United States

Site Status

Retina Macula Specialists Of Miami - LeJeune Road Office

Miami, Florida, United States

Site Status

Florida Retina Institute - Orlando

Orlando, Florida, United States

Site Status

Retina Specialty Institute - Pensacola

Pensacola, Florida, United States

Site Status

Retina Vitreous Associates of Florida - Saint Petersburg

St. Petersburg, Florida, United States

Site Status

Southern Vitreoretinal Associates, P.L. - Tallahassee

Tallahassee, Florida, United States

Site Status

Retina Consultants of Hawaii - Pali Momi Medical Center

‘Aiea, Hawaii, United States

Site Status

Retina Associates IL

Elmhurst, Illinois, United States

Site Status

University Retina and Macula Associates

Oak Forest, Illinois, United States

Site Status

Wolfe Eye Clinic - Des Moines

West Des Moines, Iowa, United States

Site Status

The Retina Care Center - Baltimore

Baltimore, Maryland, United States

Site Status

Ophthalmic Consultants of Boston - Boston

Boston, Massachusetts, United States

Site Status

Vitreo Retinal Surgery PA - Edina

Edina, Minnesota, United States

Site Status

Retina Consultants of Nevada - Summerlin

Las Vegas, Nevada, United States

Site Status

Retina Center of New Jersey

Bloomfield, New Jersey, United States

Site Status

NJ Retina - Edison Office

Edison, New Jersey, United States

Site Status

Eye Associates of New Mexico - Albuquerque - Retina Center

Albuquerque, New Mexico, United States

Site Status

Long Island Vitreoretinal Consultants - Great Neck

Great Neck, New York, United States

Site Status

Vitreoretinal Consultants of NY - Hauppauge

Hauppauge, New York, United States

Site Status

Ophthalmic Consultants of Long Island

Lynbrook, New York, United States

Site Status

Ophthalmic Consultants of the Capital Region - Troy

Troy, New York, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

Midwest Retina - Main Office

Dublin, Ohio, United States

Site Status

Retina Northwest - NW Lovejoy

Portland, Oregon, United States

Site Status

Retina Consultants, LLC

Salem, Oregon, United States

Site Status

Mid Atlantic Retina - Philadelphia / Wills Eye Hospital

Bethlehem, Pennsylvania, United States

Site Status

Erie Retinal Research

Erie, Pennsylvania, United States

Site Status

Eye Care Specialists - Kingston, PA

Kingston, Pennsylvania, United States

Site Status

Charleston Neuroscience Institute - Charleston

Charleston, South Carolina, United States

Site Status

Palmetto Retina Center - West Columbia

West Columbia, South Carolina, United States

Site Status

Black Hills Regional Eye Institute

Rapid City, South Dakota, United States

Site Status

Charles Retina Specialists - Germantown

Memphis, Tennessee, United States

Site Status

Vanderbilt University Medical School

Nashville, Tennessee, United States

Site Status

Austin Retina Associates - Central

Austin, Texas, United States

Site Status

Texas Retina Associates - Fort Worth

Fort Worth, Texas, United States

Site Status

Medical Center Ophthalmology Associates - Northwest

San Antonio, Texas, United States

Site Status

Retina Consultants of Texas - San Antonio Medical Center

San Antonio, Texas, United States

Site Status

Retina Consultants of Texas (Retina Consultants of Houston) - Texas Medical Center

The Woodlands, Texas, United States

Site Status

Retina Consultants of Texas - The Woodlands

The Woodlands, Texas, United States

Site Status

The University of Vermont Medical Center (Fletcher Allen Health Care) - Main Campus

Burlington, Vermont, United States

Site Status

Spokane Eye Clinical Research

Spokane, Washington, United States

Site Status

West Virginia University

Morgantown, West Virginia, United States

Site Status

University of Wisconsin - Madison

Madison, Wisconsin, United States

Site Status

Organizacion Medica de Investigacion (OMI)

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

OFTALMOS, Instituto Oftalmologico de Alta Complejidad

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Eyeclinic Albury Wodonga

Albury, New South Wales, Australia

Site Status

Marsden Eye Surgery Center

Parramatta, New South Wales, Australia

Site Status

Sydney Retina Clinic

Sydney, New South Wales, Australia

Site Status

Westmead Hospital

Westmead, New South Wales, Australia

Site Status

Hobart Eye Surgeons

Hobart, Tasmania, Australia

Site Status

Klinikum Klagenfurt am Wörthersee

Klagenfurt, Carinthia, Austria

Site Status

Medizinische Universität Graz

Graz, Styria, Austria

Site Status

Kepler Universitätsklinikum Campus III

Linz, Upper Austria, Austria

Site Status

Konventhospital Barmherzige Brüder Linz

Linz, Upper Austria, Austria

Site Status

Hanusch-Krankenhaus Wien

Vienna, , Austria

Site Status

SEHAT Pentagram

Sofia, , Bulgaria

Site Status

Spec. Hosp. for Active Treatment for Eye Diseases Zrenie

Sofia, , Bulgaria

Site Status

University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD

Sofia, , Bulgaria

Site Status

Multiprofile Hospital for Active Treatment Sveta Sofia | Internal Diseases Department

Sofia, , Bulgaria

Site Status

Specialized Hospital For Active Treatment of Eye Diseases Zora

Sofia, , Bulgaria

Site Status

Sveta Petka Eye Hospital

Varna, , Bulgaria

Site Status

St.Joseph's Health Care-London

London, Ontario, Canada

Site Status

Toronto Retina Institute

Toronto, Ontario, Canada

Site Status

Institut de l'Oeil des Laurentides

Boisbriand, Quebec, Canada

Site Status

The Second Hospital of Anhui medical university

Hefei, Anhui, China

Site Status

Beijing Hospital

Beijing, Beijing Municipality, China

Site Status

Beijing Tongren Hospital, Capital Medical University (East)

Beijing, Dongcheng District, China

Site Status

The 1st Affiliated Hospital Fujian Medical University

Fuzhou, Fujian, China

Site Status

Guangzhou Aier Eye Hospital

Guangzhou, Guangdong, China

Site Status

Hebei eye hospital

Hebei, Hebei, China

Site Status

Shijiazhuang General Hospital

Shijiazhuang, Hebei, China

Site Status

Henan Provincial Eye Hospital

Henan, Henan, China

Site Status

Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.

Wuhan, Hubei, China

Site Status

Union Hospt Tongji Medical Colleg. Huazhong univ. Scien&Tech

Wuhan, Hubei, China

Site Status

The First People's Hospital of Xuzhou

Xuzhou, Jiangsu, China

Site Status

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Site Status

The First Affiliated Hospital of NanChang University

Nanchang, Jiangxi, China

Site Status

Eye Center of the second Bethune Hospital, jinlin University

Changchun, Jilin, China

Site Status

Tonghua Central Hospital

Tonghua, Jilin, China

Site Status

Shenyang He Eye Specialist Hospital

Shenyang, Liaoning, China

Site Status

People's Hospital of Ningxia Hui Autonomous Region - Opthalmology

Ningxia, Ningxia, China

Site Status

The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

Site Status

Aier Eye Hospital (Chengdu)

Chengdu, Sichuan, China

Site Status

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Site Status

The 1st Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China

Site Status

ZheJiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Site Status

The Affiliated Eye Hospital of Wenzhou Medical College

Wenzhou, Zhejiang, China

Site Status

Beijing Aier Intech Eye Hospital

Beijing, , China

Site Status

Peking University People's Hospital

Beijing, , China

Site Status

Chongqing Aier Ophthalmology Hospital

Chongqing, , China

Site Status

Shanghai Tongji Hospital of Tongji University

Shanghai, , China

Site Status

Shanghai General Hospital

Shanghai, , China

Site Status

Tianjin Medical University General Hospital

Tianjin, , China

Site Status

Tianjin Eye Hospital

Tianjin, , China

Site Status

Tianjin Medical University Eye Hospital

Tianjin, , China

Site Status

Fakultní Nemocnice Hradec Kralové

Hradec Králové, , Czechia

Site Status

Fakultní nemocnice Ostrava

Ostrava, , Czechia

Site Status

Fakultni nemocnice Plzen - Lochotin

Plzen-Lochotin, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady

Prague, , Czechia

Site Status

Charles University in Prague

Prague, , Czechia

Site Status

Lexum a.s., Evropska ocni klinika

Prague, , Czechia

Site Status

Axon Clinical, s.r.o.

Prague, , Czechia

Site Status

AS Ida-Tallinna Keskhaigla - Oftalmoloogiakeskus

Tallinn, , Estonia

Site Status

Sihtasutus Tartu Ülikooli Kliinikum - Silmakliinik

Tartu, , Estonia

Site Status

Centre d'Ophtalmologie - Paradis-Monticelli

Marseille, , France

Site Status

AP-HP - Hopital Lariboisiere

Paris, , France

Site Status

Centre ophtalmologique Saint-Exupéry

Saint-Cyr-sur-Loire, , France

Site Status

LTD "Clinic LJ" - Opthalmology

Kutaisi, , Georgia

Site Status

JSC "Evex Hospitals'

Tbilisi, , Georgia

Site Status

LTD "Innova"

Tbilisi, , Georgia

Site Status

LTD "Chichua Medical Center MZERA"

Tbilisi, , Georgia

Site Status

Budapest Retina Associates

Budapest, , Hungary

Site Status

Szent-Gyorgyi Albert Orvostudomanyi Egyetem

Szeged, , Hungary

Site Status

Rambam Health Corporation

Haifa, , Israel

Site Status

Lady Davis Carmel Medical Center

Haifa, , Israel

Site Status

Hadassah Hebrew University Hospital Ein Kerem

Jerusalem, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

Assuta Medical Centers - HaShalom

Tel Aviv, , Israel

Site Status

Azienda Ospedaliera Policlinico Universitario Tor Vergata

Rome, Lazio, Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy

Site Status

Fondazione G.B.Bietti Per Lo Studio E La Ricerca In Oftalmologia

Rome, Lazio, Italy

Site Status

ASST Fatebenefratelli Sacco

Milan, Lombardy, Italy

Site Status

Ospedale San Raffaele s.r.l. - Oculistica

Milan, Lombardy, Italy

Site Status

Azienda Ospedaliero-Universitaria Di Cagliari

Cagliari, Sardinia, Italy

Site Status

A.O. di Perugia

Perugia, Umbria, Italy

Site Status

Daiyukai Daiichi Hospital

Ichinomiya, Aichi-ken, Japan

Site Status

Aichi Medical University Hospital

Nagakute, Aichi-ken, Japan

Site Status

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Kokura Memorial Hospital

Kitakyushu, Fukuoka, Japan

Site Status

Kurume University Hospital

Kurume, Fukuoka, Japan

Site Status

Southern Tohoku Eye Clinic

Kōriyama, Fukushima, Japan

Site Status

Gunma University Hospital

Maebashi, Gunma, Japan

Site Status

Sapporo City General Hospital

Sapporo, Hokkaido, Japan

Site Status

KKR Sapporo Medical Center

Sapporo, Hokkaido, Japan

Site Status

Hyogo Prefectural Amagasaki General Medical Center

Amagasaki, Hyōgo, Japan

Site Status

Kobe University Hospital

Kobe, Hyōgo, Japan

Site Status

Kozawa Eye Hospital and Diabetes Center

Mito, Ibaraki, Japan

Site Status

Kanazawa Medical University Hospital

Kahoku-gun, Ishikawa-ken, Japan

Site Status

Kanazawa University Hospital

Kanazawa, Ishikawa-ken, Japan

Site Status

Kagawa University Hospital

Kita-gun, Kagawa-ken, Japan

Site Status

Medical corporation Eiwakai Dannoue Ophthalmology clinic

Kawasaki, Kanagawa, Japan

Site Status

St. Marianna University Hospital

Kawasaki, Kanagawa, Japan

Site Status

Otakeganka Tsukimino Clinic

Yamato, Kanagawa, Japan

Site Status

Mie University Hospital

Tsu, Mie-ken, Japan

Site Status

Shinshu University Hospital

Matsumoto, Nagano, Japan

Site Status

Nara Medical University Hospital

Kashihara, Nara, Japan

Site Status

Oita University Hospital

Yufu, Oita Prefecture, Japan

Site Status

Kurashiki Medical Center

Kurashiki, Okayama-ken, Japan

Site Status

Okayama University Hospital

Okayama, Okayama-ken, Japan

Site Status

University of the Ryukyus Hospital

Nakagami, Okinawa, Japan

Site Status

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Site Status

Kansai Medical University Medical Center

Moriguchi, Osaka, Japan

Site Status

Kindai University Hospital

Osakasayama-shi, Osaka, Japan

Site Status

The University of Tokyo Hospital

Bunkyo-ku, Tokyo, Japan

Site Status

St.Luke's International Hospital

Chuoku, Tokyo, Japan

Site Status

Nishikasai Inouye Eye Hospital

Edogawa-ku, Tokyo, Japan

Site Status

Tokyo Medical University Hachioji Medical Center

Hachiōji, Tokyo, Japan

Site Status

Tokiwadai Muranaka Eye Clinic

Itabashi-ku, Tokyo, Japan

Site Status

National Hospital Organization Tokyo Medical Center

Meguro-ku, Tokyo, Japan

Site Status

Keio University Hospital

Shinjuku-ku, Tokyo, Japan

Site Status

Tokyo Women's Medical University Hospital

Shinjuku-ku, Tokyo, Japan

Site Status

Yamaguchi University Hospital

Ube, Yamaguchi, Japan

Site Status

University of Yamanashi Hospital

Chūō, Yamanashi, Japan

Site Status

Akita University Hospital

Akita, , Japan

Site Status

Hayashi Eye Hospital

Fukuoka, , Japan

Site Status

Fukushima Medical University Hospital

Fukushima, , Japan

Site Status

Hiroshima University Hospital

Hiroshima, , Japan

Site Status

University of Miyazaki Hospital

Miyazaki, , Japan

Site Status

Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, , Japan

Site Status

Japanese Red Cross Saitama Hospital

Saitama, , Japan

Site Status

Tokushima University Hospital

Tokushima, , Japan

Site Status

Japanese Red Cross Wakayama Medical center

Wakayama, , Japan

Site Status

Yamagata University Hospital

Yamagata, , Japan

Site Status

Department of Ophthalmology

Riga, , Latvia

Site Status

Latvian American Eye Center

Riga, , Latvia

Site Status

Riga East Clinical University Hospital "Gailezers"

Riga, , Latvia

Site Status

Hospital of LT University of Health Sciences Kaunas Clinics

Kaunas, , Lithuania

Site Status

PI Klaipedos University Hospital

Klaipėda, , Lithuania

Site Status

Vilnius University Hospital Santaros Klinikos

Vilnius, , Lithuania

Site Status

ALM Oftalmolaser - Oftalmologia Medica e Cirurgica

Lisbon, Lisbon District, Portugal

Site Status

AIBILI

Coimbra, , Portugal

Site Status

Espaco Medico de Coimbra

Coimbra, , Portugal

Site Status

Centro Hospitalar Universitario do Porto

Porto, , Portugal

Site Status

Centro Hospitalar Vila Nova de Gaia e Espinho | Unit 1 - Clinical Research Center

Porto, , Portugal

Site Status

Scientific Research Institution of Ophthalmic Diseases

Moscow, , Russia

Site Status

FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov

Moscow, , Russia

Site Status

Clinical Center of Serbia

Belgrade, , Serbia

Site Status

Clinical hospital center Zvezdara

Belgrade, , Serbia

Site Status

Klinicki centar Vojvodine

Novi Sad, , Serbia

Site Status

National University Hospital Medical Centre

Singapore, , Singapore

Site Status

Singapore National Eye Centre

Singapore, , Singapore

Site Status

Fakultna nemocnica Nitra

Nitra, , Slovakia

Site Status

Nemocnica s Poliklinikou Trebisov, Svet zdravia a.s.

Trebišov, , Slovakia

Site Status

Fakultna nemocnica Trencin

Trenčín, , Slovakia

Site Status

Fakultna nemocnica s poliklinikou Zilina

Žilina, , Slovakia

Site Status

Nune Eye Hospital - Retina Center Ophthalmology

Seoul, Gangnam-gu, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggido, South Korea

Site Status

Asan Medical Center - Oncology Department

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Pusan National University Hospital

Busan, , South Korea

Site Status

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status

Seoul National University Hospital (b)

Seoul, , South Korea

Site Status

Samsung Medical Center - Oncology Department

Seoul, , South Korea

Site Status

Instituto Oftalmologico Gomez-Ulla S.L. - Oftalmologia

Santiago de Compostela, A Coruña, Spain

Site Status

Hospital Clínic i Provincial de Barcelona

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau | Gynecology Department

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia - Oftalmologia

Córdoba, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Hospital Universitario Y Politecnico La Fe - Oftalmologia

Valencia, , Spain

Site Status

Hospital Universitario Miguel Servet - Oftalmologia

Zaragoza, , Spain

Site Status

RétinElysée

Lausanne, Canton of Vaud, Switzerland

Site Status

Berner Augenklinik am Lindenhofspital

Bern, , Switzerland

Site Status

Stadtspital Triemli

Zurich, , Switzerland

Site Status

Shin Kong Wu Ho-Su Memorial Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital at Linkou

Taoyuan District, , Taiwan

Site Status

Private Enterprise Private Production Company "Acinus", Treatment and Diagnostic Center

Kropyvnytskyi, , Ukraine

Site Status

Centralna Polyclinica MVS Ukraiiny

Kyiv, , Ukraine

Site Status

Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi

Poltava, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Bulgaria Canada China Czechia Estonia France Georgia Hungary Israel Italy Japan Latvia Lithuania Portugal Russia Serbia Singapore Slovakia South Korea Spain Switzerland Taiwan Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology. 2025 Aug 26:S0161-6420(25)00532-9. doi: 10.1016/j.ophtha.2025.08.022. Online ahead of print.

Reference Type DERIVED
PMID: 40876598 (View on PubMed)

Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7.

Reference Type DERIVED
PMID: 38461841 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.bayer.com/

Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-003851-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

20968

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect Aflibercept on Ocular Perfusion
NCT03804099 COMPLETED PHASE4